OGEN ORAGENICS INC.

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania.

These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.

2025 BIO International Convention

  • Dates: June 16–19, 2025

  • Location: Boston Convention & Exhibition Center, Boston, MA

  • Presentation Date & Time: June 19, 2025, from 11:30 AM – 11:45 AM ET

  • Registration:

42nd Annual National Neurotrauma Society (NNS) Symposium

  • Dates: June 15–18, 2025

  • Location: Philadelphia Marriott Downtown, Philadelphia, PA

  • Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care

About Oragenics, Inc.

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company’s intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit .

Investor Contact:

Rich Cockrell

CG Capital

866.889.1972

tal



EN
10/06/2025

Underlying

OGENORAGENICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ORAGENICS INC.

 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to S...

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the trea...

July 16, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics Completes Approximately $16.5 Million Offering

Oragenics Completes Approximately $16.5 Million Offering Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury SARASOTA, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing of its previously announced public offering of Series H Convertible Preferred Stock and Warrants. The Company secured total gross proceeds of approximately $16.5 million. As part of the ...

July 2, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Mill...

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock ...

July 1, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics to Present at 2025 BIO International Convention and Attend 4...

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15...

June 10, 2025 1 EN
 PRESS RELEASE
Free
OGEN ORAGENICS INC.

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the “Board”) on May 27, 2025 approved a One-for-Thirty (1-for-30) reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Reverse Stock Split”). As a result of the Reverse Stock Split, the Company’s common stock is expecte...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch